In a ruling that could reshape India’s heart drug market, the Indian Patent Office has revoked Novartis’ patent for its blockbuster therapy Vymada (sold internationally as Entresto). The decision, issued on September 12, found that Novartis’ claims lacked novelty, inventive step, and sufficient proof of enhanced efficacy.